Cargando…

Role of Combined (68)Ga DOTA-Peptides and (18)F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms

This review article summarizes the role of combined (68)Ga DOTA-peptides and (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in the evaluation of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Patients with GEP-NENs can initially present themselv...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaewput, Chalermrat, Vinjamuri, Sobhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871217/
https://www.ncbi.nlm.nih.gov/pubmed/35204371
http://dx.doi.org/10.3390/diagnostics12020280
_version_ 1784656944168960000
author Kaewput, Chalermrat
Vinjamuri, Sobhan
author_facet Kaewput, Chalermrat
Vinjamuri, Sobhan
author_sort Kaewput, Chalermrat
collection PubMed
description This review article summarizes the role of combined (68)Ga DOTA-peptides and (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in the evaluation of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Patients with GEP-NENs can initially present themselves to a gastroenterologist or endocrinologist rather than cancer specialist; hence, it is vital for a wider group of clinicians to be familiar with the range of tests available for the evaluation of these patients. The role of PET scanning by using (68)Ga DOTA-peptides has a high sensitivity in the diagnosis of GEP-NENs and to guide patient selection for treatment with somatostatin analogues (SSA) and/or peptide receptor radionuclide therapy (PRRT). The loss of somatostatin receptor (SSTR) expression was found to be associated with an increased glucose metabolism in cells. However, the routine use of SSTR targeted radiotracers in combination with (18)F-FDG to evaluate glucose utilization in GEP-NENs is still debatable. In our opinion, in patients with NENs, (18)F-FDG PET should be performed in the case of a negative or slightly positive (68)Ga DOTA-peptides PET scan for assessing the dedifferentiation status, to guide correct therapeutic strategy and to evaluate the prognosis. The approach of combined receptor and metabolic imaging can improve diagnostic accuracy, especially considering the heterogeneity of these lesions. Therefore, (68)Ga DOTA-peptides and (18)F-FDG PET should be considered complementary in patients with GEP-NENs.
format Online
Article
Text
id pubmed-8871217
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88712172022-02-25 Role of Combined (68)Ga DOTA-Peptides and (18)F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms Kaewput, Chalermrat Vinjamuri, Sobhan Diagnostics (Basel) Review This review article summarizes the role of combined (68)Ga DOTA-peptides and (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in the evaluation of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Patients with GEP-NENs can initially present themselves to a gastroenterologist or endocrinologist rather than cancer specialist; hence, it is vital for a wider group of clinicians to be familiar with the range of tests available for the evaluation of these patients. The role of PET scanning by using (68)Ga DOTA-peptides has a high sensitivity in the diagnosis of GEP-NENs and to guide patient selection for treatment with somatostatin analogues (SSA) and/or peptide receptor radionuclide therapy (PRRT). The loss of somatostatin receptor (SSTR) expression was found to be associated with an increased glucose metabolism in cells. However, the routine use of SSTR targeted radiotracers in combination with (18)F-FDG to evaluate glucose utilization in GEP-NENs is still debatable. In our opinion, in patients with NENs, (18)F-FDG PET should be performed in the case of a negative or slightly positive (68)Ga DOTA-peptides PET scan for assessing the dedifferentiation status, to guide correct therapeutic strategy and to evaluate the prognosis. The approach of combined receptor and metabolic imaging can improve diagnostic accuracy, especially considering the heterogeneity of these lesions. Therefore, (68)Ga DOTA-peptides and (18)F-FDG PET should be considered complementary in patients with GEP-NENs. MDPI 2022-01-22 /pmc/articles/PMC8871217/ /pubmed/35204371 http://dx.doi.org/10.3390/diagnostics12020280 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kaewput, Chalermrat
Vinjamuri, Sobhan
Role of Combined (68)Ga DOTA-Peptides and (18)F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms
title Role of Combined (68)Ga DOTA-Peptides and (18)F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms
title_full Role of Combined (68)Ga DOTA-Peptides and (18)F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms
title_fullStr Role of Combined (68)Ga DOTA-Peptides and (18)F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms
title_full_unstemmed Role of Combined (68)Ga DOTA-Peptides and (18)F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms
title_short Role of Combined (68)Ga DOTA-Peptides and (18)F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms
title_sort role of combined (68)ga dota-peptides and (18)f fdg pet/ct in the evaluation of gastroenteropancreatic neuroendocrine neoplasms
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871217/
https://www.ncbi.nlm.nih.gov/pubmed/35204371
http://dx.doi.org/10.3390/diagnostics12020280
work_keys_str_mv AT kaewputchalermrat roleofcombined68gadotapeptidesand18ffdgpetctintheevaluationofgastroenteropancreaticneuroendocrineneoplasms
AT vinjamurisobhan roleofcombined68gadotapeptidesand18ffdgpetctintheevaluationofgastroenteropancreaticneuroendocrineneoplasms